Oligonucleotide Therapeutics: From Discovery and Development to Patentability

Area of Science:

• Biotechnology and Pharmaceutical Sciences
• Molecular Biology
• Drug Discovery

Background:

• The development of oligonucleotide-based therapies has progressed from initial proof-of-concept to market authorization.
• Over a dozen oligonucleotide therapeutics are now approved, with many more in clinical development, indicating significant industry investment and validation.
• Early applications focused on rare diseases, but advancements now enable broader patient population benefits.

Purpose of the Study:

• To provide a comprehensive overview of therapeutic oligonucleotides.
• To detail the various types of oligonucleotides, their mechanisms of action, and delivery methods.
• To discuss current therapeutic areas, patenting strategies, and future prospects for oligonucleotide drug discovery.

Main Methods:

• Review of existing literature and market-authorized oligonucleotide therapies.
• Analysis of technological advancements in oligonucleotide pharmacokinetics and pharmacodynamics.
• Examination of patenting landscapes and therapeutic applications.

Main Results:

• Twelve oligonucleotide therapeutics have been approved since the first marketing authorization.
• Technologies have been developed to enhance oligonucleotide delivery and efficacy.
• Oligonucleotides are increasingly targeting larger patient populations beyond rare diseases.

Conclusions:

• Therapeutic oligonucleotides represent a significant advancement in medicine, offering alternatives to traditional protein-targeting drugs.
• Continued innovation in oligonucleotide technology promises further improvements and broader therapeutic applications.
• The field presents ongoing challenges and substantial opportunities for future drug discovery and development.